methylprednisolone acetate has been researched along with Peripheral Nerve Diseases in 2 studies
Methylprednisolone Acetate: Methylprednisolone derivative that is used as an anti-inflammatory agent for the treatment of ALLERGY and ALLERGIC RHINITIS; ASTHMA; and BURSITIS; and for the treatment of ADRENAL INSUFFICIENCY.
methylprednisolone acetate : An acetate ester resulting from the formal condensation of the 21-hydroxy function of 6alpha-methylprednisolone compound with acetic acid.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scuderi, GJ | 1 |
| Cuellar, JM | 1 |
| Cuellar, VG | 1 |
| Yeomans, DC | 1 |
| Carragee, EJ | 1 |
| Angst, MS | 1 |
| Warfield, CA | 1 |
| Crews, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Using Inflammatory Biomarkers and EMG Results to Predict Epidural Injection Response in Patients Diagnosed With Lumbar Stenosis[NCT03511053] | 11 participants (Actual) | Interventional | 2017-12-19 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measures how pain is affecting the patients lifestyle on a scale from 0 to 10 as defined by each question. The questionnaire contains 15 questions that each range on a scale form 0 to 10. The total score of the questionnaire ranges from 0 to 150. Lower values represent a better outcome. (NCT03511053)
Timeframe: Change between baseline, 1 month and 2 months post injection
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Average at baseline | Average at 1 month | Average at 2 months | Average at 1 month change | Average at 2 month change | |
| All Participants | 77.5 | 53.3 | 64.3 | 27.3 | 16.2 |
Measures how pain due to spinal stenosis is effected the patient based on quality of life/pain questions and satisfaction questions for months 1 and 2 (no scales are used) SSSQ scores are reported in percentages 0-100%, higher scores indicate worse outcomes. (NCT03511053)
Timeframe: Change between baseline, 1 month and 2 months post injection
| Intervention | Percentage (Mean) | ||||
|---|---|---|---|---|---|
| Average at baseline | Average at 1 month | Average at 2 months | Average at 1 month change | Average at 2 month change | |
| All Participants | 64.1 | 53.2 | 53.5 | 11.7 | 10.3 |
Number rating of back/leg pain from 0 to 10, 0 being no pain/discomfort, 10 being extreme pain/discomfort (NCT03511053)
Timeframe: Change between baseline, 1 month and 2 months post injection
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Average at baseline | Average at 1 month | Average at 2 months | Average 1 month change | Average 2 month change | |
| All Participants | 6.2 | 5.0 | 5.0 | 0.8 | 1 |
2 other studies available for methylprednisolone acetate and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Epidural interferon gamma-immunoreactivity: a biomarker for lumbar nerve root irritation.
Topics: Adult; Aged; Biomarkers; Bupivacaine; Cohort Studies; Epidural Space; Female; Follow-Up Studies; Hum | 2009 |
Work status and response to epidural steroid injection.
Topics: Adult; Female; Humans; Injections, Epidural; Male; Methylprednisolone; Methylprednisolone Acetate; M | 1987 |